Zoll's posts positive defibrillator data; Cognoptix kicks off trials for Alzheimer's Dx;

 @FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev

 @MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce

 @DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce

> Zoll's defibrillators helped double the survival rate of out-of-hospital cardiac arrest, a new study suggests. Release

> A Theragenics ($TGX) subsidiary is rolling out a new line of peripherally inserted central catheters. Item

> Diagnostics maker Cognoptix is kicking off a clinical trial of its Alzheimer's diagnostic that detects a beta amyloid signature in patients' eyes. More

> 2012 Fierce 15 winner T2 Biosystems has secured a patent that will allow it to develop a real-time, in vivo application of its T2MR diagnostics platform. News

> Amedica nailed down a new U.S. patent for an artificial spine disc implant using the company's proprietary Silicon Nitride ceramic material. Release

> The Atlantic takes a look at the FDA's 510(k) loophole that has put many high-risk devices on the market without much clinical evidence of safety and efficacy. Article

> Looking at a meta-analysis of 7 studies, researchers determined that Medtronic's ($MDT) Pillar treatment for obstructive sleep apnea significantly reduced snoring volume. Report

Biotech News

 @FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech

 @JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce

 @RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce

> Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article

> Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs. More

> Takeda snags rights to lupus drugs from Seattle upstart in $255M deal. News

Pharma News

 @FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma

 @EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce

> Valeant Pharmaceuticals ($VRX) swung to a loss in the fourth quarter, thanks to charges related to its Medicis Pharmaceutical buyout. Report | Release

> Indian generics maker Cipla hiked its offer for South Africa's Cipla Medpro by 17%, bringing its bid to $512 million. Report

> Lundbeck won European approval for Selincro, a treatment for alcohol dependency that's key to the Danish drugmaker's growth strategy. Report

> Ipsen posted a full-year loss of €29 million ($37.9 million) after pulling out of the hemophilia treatment market. Report

> An Indian court put Cadila Pharmaceuticals on notice after the drugmaker failed to raise employees' salaries as ordered by an industrial tribunal. Report

Vaccines News

> FDA panel endorses quadrivalents, setting stage for new flu market. Article

> Is it too soon to quit on Nabi's nicotine vaccine? More

> Seasonal flu vaccine only 56% effective. Story

> GSK facing competition from Sanofi's 6-in-1 shot. Item

> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report

Pharma Manufacturing News

> Ranbaxy problems overshadow manufacturing expansion. Article

> Qualicaps adds new technology as part of expansion. Item

> FDA warning to Abbey questions quality of API for sterile drugs. Story

> Hospira manufacturing problems arise at an inopportune time. More

And Finally... Autism shares genetic features with four other psychiatric disorders, including bipolar disorder and schizophrenia. Report